<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691897</url>
  </required_header>
  <id_info>
    <org_study_id>CT-93-7817</org_study_id>
    <nct_id>NCT02691897</nct_id>
  </id_info>
  <brief_title>Melatonin's Effects on Treatment Of Diabetes Mellitus</brief_title>
  <acronym>METOD</acronym>
  <official_title>The Effects of Melatonin on Serum Glucose Levels of Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy and safety of melatonin in control of blood
      sugar in patients with type 2 diabetes mellitus (DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus (DM) is a major public health problem with increasing worldwide incidence.
      The main causes for increase in incidence of DM are inactivity, obesity and changes of
      dietary habits. Investigators think that the changes in the awake-sleep cycle may also
      contribute to higher incidence of DM in recent years. Melatonin is an important component of
      the circadian system. Numerous experimental studies have demonstrated that melatonin has many
      beneficial actions.Melatonin is a potent antioxidant, reduces inflammatory process, lowers
      blood pressure, improve lipid profiles. Collectively, these data suggest that melatonin may
      be useful in control of blood sugar in patients with DM.

      The aim of this study is to assess the efficacy of melatonin in control of blood sugar in
      patients with type 2 DM.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood sugar (FBS)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (Body mass index)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aminotransferases</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 3mg once daily at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet once daily at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin 3mg once daily at bedtime</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet once daily at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus diagnosed by an endocrinologist for more than six months

          -  FBS=120-160mg/dl

          -  HbA1C&lt;8%

        Exclusion Criteria:

          -  Melatonin sensitivity

          -  Impaired fasting glucose (IFG)

          -  Impaired glucose tolerance (IGT)

          -  Under Insulin therapy

          -  Pregnancy

          -  Lactation

          -  Diabetic autonomic neuropathy and orthostatic hypotension

          -  Renal failure (Creatinin&gt;1.5mg/dl)

          -  Diabetic retinopathy

          -  Diabetic nephropathy

          -  Malignancy

          -  Alcohol use

          -  Liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran Bagheri Lankarani, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mesbah Shams, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seied Mohammad Hosseini saadi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Payam Peymani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Motahhari Clinic, Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mesbah Shams, MD</investigator_full_name>
    <investigator_title>Associate professor of Internal Medicine &amp; Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Blood Glucose</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>Pineal gland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

